Immunological monitoring in cyclosporine-treated patients.
The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on lymphokine production by T lymphocytes. Most efforts to assess immunosuppression in CsA-treated patients have concentrated on measuring some aspect of activated T cell function. These have included monitoring of lymphocyte subsets and the appearance of activated T cell markers, assaying the production of lymphokines and the direct measurement of lymphokines in serum and urine, and most recently measurement of soluble interleukin-2 receptor (SIL2R). Using a new microparticle enzyme immunoassay (MEIA) in a preliminary study of 12 CsA-treated renal transplant recipients, we found significant increases in serum SIL2R levels in patients with rejection and we conclude that MEIA may have some use in the monitoring of CsA-treated patients.